TOPIC:

Prevalence of Resistance-Associated Substitutions in HCV 7 years 9 months ago #19177

LondonGirl
Topic Author
Offline
Platinum Member
Posts: 1366
Karma: 17
Thank you received: 2124

"This paper, which some Drs feel is important, not least for NHS patients in England" :(a leading NHS consultant).

Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment with Ledipasvir and Sofosbuvir

"We evaluated the effects of baseline hepatitis C virus (HCV) NS5A, NS5B, and NS3 resistance-associated substitutions (RASs) on response to the combination of ledipasvir and sofosbuvir, with or without ribavirin, in patients with HCV genotype 1 infection".

www.gastrojournal.org/article/S0016-5085...%2Fpubmed%2F27296509

GT1a Dec14 F2/8.7 VL 900000-2.5M
Jan16 Hepcivir-L MonkMed/Redemption
Baseline: VL 913575 Alt 76 Platelets low
Wk2 VL1157 Alt 23
DET Wk 8 VL 32 Alt19 'In the slow lane'
June16 Fibro 5.7 F0/1 LIF 1.5
Wk 11 VL<12 Alt 13 Det/Unq
Extending tx 12 wks Mylan Sofo/Dac MonkMed
Wk 14 VL <12 Det/Unq
Wk 16 VL UNDETECTED
Wk 22 + 4 Wks Sunprevir FixHepC
Wk 24 UNDETECTED Alt 13
Wk 12 post tx SVR12 Wk 26 SVR24
Thank-you Tim, Dr Debasis @ MonkMed & Dr Freeman @ Fix HepC

The following user(s) said Thank You: DrJames, pat1, GT2, fitz

Prevalence of Resistance-Associated Substitutions in HCV 7 years 9 months ago #19178

GT2
Offline
Elite Member
Posts: 295
Karma: 9
Thank you received: 970

Good News for GT1s

Conclusions
Baseline RASs in NS5A have minimal effects on patients’ response to ledipasvir/sofosbuvir therapy. When these RASs do have effects, they could be largely overcome by extending treatment duration or through treatment intensification.

1983: Hospitalised with Acute non-A, non-B Hepatitis after ICU blood transfusion 3mths earlier => HCV GT2
22/02/16: (pre-tmt) ALT 61, VL 2.48 IU/ml Hepascore 0.32 (F1/2), fatigue, brain fog, bloating (Treatment Naïve)
10/04/16: (Start tmt) Sofovir +DaclaHep (SOF + DCV) by Hetero Labs in India
09/05/16: ALT 34, VL: NOT Detected :cheer:

, FBG 11.9 :huh:

17/6/16 FBG 5.7; PPBG (@14.22) 6.9 (@ 20.45) 7.1; BP 124/72

(Accu-Chek Mobile & Omron Auto BP Monitor)

The following user(s) said Thank You: LondonGirl, pat1, fitz

Prevalence of Resistance-Associated Substitutions in HCV 7 years 9 months ago #19232

LondonGirl
Topic Author
Offline
Platinum Member
Posts: 1366
Karma: 17
Thank you received: 2124

Yes, good news, but good to be aware for the small % - So that those in the 'slow-lane' can know there is the option to extend treatment if necessary with generics safely via this website in time; especially if they are being treated by NHS England who are not always prescribing the recommended tx period and generally not offering any treatment extention from what I've heard.

GT1a Dec14 F2/8.7 VL 900000-2.5M
Jan16 Hepcivir-L MonkMed/Redemption
Baseline: VL 913575 Alt 76 Platelets low
Wk2 VL1157 Alt 23
DET Wk 8 VL 32 Alt19 'In the slow lane'
June16 Fibro 5.7 F0/1 LIF 1.5
Wk 11 VL<12 Alt 13 Det/Unq
Extending tx 12 wks Mylan Sofo/Dac MonkMed
Wk 14 VL <12 Det/Unq
Wk 16 VL UNDETECTED
Wk 22 + 4 Wks Sunprevir FixHepC
Wk 24 UNDETECTED Alt 13
Wk 12 post tx SVR12 Wk 26 SVR24
Thank-you Tim, Dr Debasis @ MonkMed & Dr Freeman @ Fix HepC

The following user(s) said Thank You: pat1, fitz